Ventilation strategies in ards
Reading File
Finding Sources
Finding Sources
Searching PubMed
"acute respiratory distress syndrome" AND "mechanical ventilation"
Searching the Web
ARDS ventilation strategies 2024 2025 guidelines lung protective
Reading File
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from multiple sources. Let me compile the full, detailed answer.
Ventilation Strategies in ARDS
1. Berlin Definition and Severity Classification
ARDS is defined by: acute onset within 7 days of a clinical insult, bilateral infiltrates on chest imaging not fully explained by effusions or collapse, respiratory failure not fully explained by cardiac failure or fluid overload, and impaired oxygenation (PaO2/FiO2 ratio):
| Severity | PaO2/FiO2 | PEEP |
|---|---|---|
| Mild | 200-300 mmHg | ≥ 5 cmH2O |
| Moderate | 100-200 mmHg | ≥ 5 cmH2O |
| Severe | < 100 mmHg | ≥ 5 cmH2O |
Mortality ranges from ~27% (mild) to ~45% (severe). The key pathophysiology is heterogeneous lung injury: CT shows patchy opacities with normal-appearing areas interspersed, meaning positive pressure preferentially inflates compliant zones, risking overdistension.
2. Ventilator-Induced Lung Injury (VILI): The Core Problem
Before applying any strategy, understanding the four VILI mechanisms is essential:
- Volutrauma - overdistension of alveoli by excessive tidal volume
- Barotrauma - injury from excessive airway/plateau pressure
- Atelectrauma - repetitive opening and closing of unstable alveoli with each breath cycle (shear stress)
- Biotrauma - mechanotransduction triggering local and systemic inflammatory cytokine release
All ventilation strategies in ARDS aim to minimize these four injury types while maintaining adequate gas exchange.
3. Lung-Protective Ventilation (LPV) - The Foundation
This is the only ventilation strategy proven to reduce mortality in ARDS.
Tidal Volume Limitation
The landmark ARDSNet ARMA trial (2000) randomized 861 patients to:
- Low tidal volume: 6 mL/kg predicted body weight (PBW), plateau pressure ≤ 30 cmH2O
- Conventional: 12 mL/kg PBW, plateau pressure ≤ 50 cmH2O
Result: 22% relative mortality reduction (31% vs 40%) in the low tidal volume group. Current ATS and ESICM guidelines strongly recommend tidal volumes of 4-8 mL/kg PBW with a target of 6 mL/kg.
PBW is based on height and sex - NOT actual body weight. This distinction is critical: tidal volume must be based on the normal lung size, not the patient's actual mass.
- Murray & Nadel's Textbook of Respiratory Medicine, p. 3158 (ARDSNet trial data)
- Washington Manual of Medical Therapeutics, p. 289
Plateau Pressure
- Target: ≤ 30 cmH2O
- Plateau pressure reflects static compliance and is a surrogate for end-inspiratory alveolar pressure
- If plateau pressure exceeds 30, reduce tidal volume down to 4 mL/kg PBW even at the expense of hypercapnia
Driving Pressure (ΔP)
Driving pressure = Plateau pressure - PEEP = Tidal Volume / Respiratory System Compliance
- Emerging evidence shows driving pressure may be a better predictor of VILI than tidal volume alone (Amato et al., 2015)
- A 2024 meta-analysis (PMID 38937217) found driving pressure-guided ventilation reduces postoperative pulmonary complications
- Target driving pressure < 14 cmH2O is associated with improved outcomes
- Practically: if PEEP is increased and plateau pressure does not rise proportionally, ΔP falls, suggesting successful recruitment
4. PEEP Strategy
PEEP serves to:
- Prevent alveolar derecruitment (reducing atelectrauma)
- Increase functional residual capacity
- Improve oxygenation by keeping previously collapsed alveoli open
ARDSNet PEEP/FiO2 Tables
Two commonly used titration tables from ARDSNet:
Lower PEEP / Higher FiO2 table:
| FiO2 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 0.7 | 0.7 | 0.8 | 0.9 | 0.9 | 1.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEEP | 5 | 5 | 8 | 8 | 10 | 10 | 10 | 12 | 14 | 14 | 14 | 16 | 18-24 |
Higher PEEP / Lower FiO2 table (for moderate-severe ARDS):
| FiO2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.4 | 0.5 | 0.5-0.8 | 0.8 | 0.9 | 1.0 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PEEP | 5 | 8 | 10 | 12 | 14 | 14 | 16 | 16 | 18 | 20 | 22 | 22-24 |
The ALVEOLI and LOVS trials compared high vs low PEEP strategies and showed no difference in 28-day mortality in the overall ARDS population, though meta-analyses suggest higher PEEP may benefit moderate-severe ARDS (PaO2/FiO2 < 200).
Electrical impedance tomography (EIT) for PEEP titration - a 2025 systematic review (PMID 40011398) found EIT-guided PEEP titration reduces overdistension while maintaining recruitment.
Recruitment Maneuvers
Transient increases in airway pressure (e.g., 40 cmH2O CPAP for 40 seconds) to reopen collapsed alveoli. The ART trial (2017) found that recruitment maneuvers + high PEEP titration increased 28-day mortality, so sustained high-pressure recruitment maneuvers are not recommended routinely. Brief, gentle maneuvers may be used after disconnection from the ventilator.
5. Permissive Hypercapnia
To achieve low tidal volumes and low plateau pressures, CO2 retention is accepted:
- Target pH: 7.20-7.35 is generally tolerated (Washington Manual)
- Bicarbonate infusion may be used to correct pH if needed
- Contraindicated when raised intracranial pressure is present (cerebral vasodilation from CO2 is harmful)
- Also relatively contraindicated in severe pulmonary hypertension (hypercapnia increases PVR)
6. Prone Positioning
Mechanism: In supine ARDS, the dependent (dorsal) lung zones are compressed and collapsed. Proning redistributes perfusion to now-ventral (previously dorsal) regions while redistributing ventilation more homogeneously, thus improving V/Q matching and reducing VILI.
PROSEVA Trial (2013): 474 patients with severe ARDS (PaO2/FiO2 < 150 mmHg). Prone positioning for ≥ 16 hours/day reduced 28-day mortality from 32.8% to 16.0% (absolute risk reduction ~17%). This is the strongest single non-pharmacologic intervention in ARDS.
Indications: Moderate-severe ARDS (PaO2/FiO2 < 150 mmHg) despite optimal conventional ventilation. Both ATS and ESICM guidelines give this a strong recommendation.
Extended prone positioning - a 2026 meta-analysis (PMID 41631378) examined extended (>16 h) proning and found sustained benefit.
Awake prone positioning - ESICM guidelines suggest considering awake prone positioning in spontaneously breathing patients to potentially avoid intubation (widely used during COVID-19).
Complications: Pressure ulcers, endotracheal tube displacement, vascular access dislodgement, facial edema, brachial plexus injury.
7. Neuromuscular Blockade (NMB)
ACURASYS Trial (2010): 48 hours of cisatracurium infusion in moderate-severe ARDS improved 90-day survival and reduced barotrauma. Proposed mechanisms include:
- Elimination of patient-ventilator dyssynchrony
- Reduction in oxygen consumption and CO2 production
- Possible direct anti-inflammatory effect
ROSE Trial (2019): Challenged ACURASYS by showing that early NMB with cisatracurium did not reduce 90-day mortality vs. light sedation in ARDS. However, this trial used a lighter sedation protocol in the control arm, which likely minimized dyssynchrony.
Current practice: NMB may be considered in severe ARDS with refractory hypoxemia or severe dyssynchrony, but routine early use in all ARDS patients is not supported.
8. Oxygenation Targets
- SpO2: 88-95% (ARDSNet protocol) or PaO2 55-80 mmHg
- Avoid excessive FiO2 (oxygen toxicity) but maintain adequate delivery
- Liberal oxygenation targets (SpO2 > 96%) have not been shown to improve outcomes and may worsen them in critically ill patients
9. Volume-Control vs. Pressure-Control Ventilation
- No RCT has shown a mortality difference between VC and PC modes in ARDS
- Pressure control generates a decelerating flow waveform, leading to higher mean airway pressure and potentially better recruitment of slow time-constant alveoli
- Volume control guarantees delivered tidal volume regardless of compliance changes, which may be advantageous when compliance is evolving rapidly
- Most centers use VC-AC (volume control, assist-control) as the default, incorporating LPV targets
10. High-Frequency Oscillatory Ventilation (HFOV)
Delivers very small tidal volumes (1-5 mL/kg) at high frequencies (typically 3-8 Hz) around a constant high mean airway pressure. Theoretically ideal for VILI prevention.
Two large RCTs (OSCILLATE and OSCAR, 2013) showed:
- No mortality benefit vs. conventional LPV
- OSCILLATE suggested HFOV may be harmful (increased mortality), possibly due to sedation requirements or hemodynamic compromise from high mean airway pressures
Conclusion: Routine HFOV cannot be recommended for ARDS. - Murray & Nadel's, p. 3159
11. Airway Pressure Release Ventilation (APRV)
- Maintains a prolonged high CPAP level (P-high) with brief, intermittent releases (P-low)
- Allows spontaneous breathing throughout the cycle
- Theoretically improves recruitment and reduces sedation/NMB needs
- No large RCT has demonstrated a mortality benefit; evidence is limited to small trials
- May cause patient-ventilator asynchrony and dyssynchrony-related VILI
12. Refractory Hypoxemia - Rescue Strategies
When conventional LPV + PEEP + proning fails, consider:
| Strategy | Mechanism | Evidence |
|---|---|---|
| Prone positioning | V/Q redistribution | Strong (PROSEVA) |
| Inhaled nitric oxide (iNO) | Selective pulmonary vasodilation in ventilated areas | Improves oxygenation transiently; no mortality benefit; risk of renal dysfunction |
| Inhaled prostacyclins | Selective pulmonary vasodilation | Improves oxygenation and PAP; no mortality data; antiplatelet effect |
| Neuromuscular blockade | Eliminates dyssynchrony | Consider in severe ARDS |
| VV-ECMO | Extracorporeal gas exchange allowing "ultra-protective" ventilation | CESAR and EOLIA trials: benefit in severe ARDS at ECMO centers |
ECMO: The EOLIA trial (2018) showed a trend toward benefit with VV-ECMO in severe ARDS (PaO2/FiO2 < 80 despite optimal care) but did not reach statistical significance for the primary endpoint. Bayesian analyses and subsequent data support its use in selected patients at specialized centers.
13. Fluid Management
The FACTT trial (ARDSNet) showed that conservative fluid management (targeting CVP < 4 mmHg or PCWP < 8 mmHg) was associated with:
- More ventilator-free days
- More ICU-free days
- No difference in 60-day mortality
Conservative fluids reduce pulmonary edema formation, which is beneficial given the leaky alveolar-capillary barrier in ARDS. However, avoid hypovolemia that compromises organ perfusion.
14. Pharmacological Adjuncts
Corticosteroids
- Early/mid-course ARDS (< 14 days): Some trials (LaSRS, DEXA-ARDS) show modest benefit in reducing ventilator days; evidence is mixed
- Late ARDS (> 14 days): Potentially harmful, associated with increased mortality and infections
- A 2025 systematic review (PMID 40597594) found corticosteroids reduce mortality in select critically ill patients but requires individualized decisions
- Exception: Strong evidence supports dexamethasone in severe COVID-19-related ARDS (RECOVERY trial: 35% relative mortality reduction)
Inhaled Pulmonary Vasodilators
- Nitric oxide: No mortality benefit; improves P/F ratio transiently; risk of renal failure - Washington Manual, p. 289
- Inhaled prostacyclins: Improve oxygenation and pulmonary artery pressure; no mortality data; antiplatelet effect is a concern
15. Summary: Ventilation Bundle for ARDS
| Parameter | Target |
|---|---|
| Tidal volume | 4-6 mL/kg PBW (max 8 mL/kg) |
| Plateau pressure | ≤ 30 cmH2O |
| Driving pressure | < 14 cmH2O |
| PEEP | Titrate per ARDSNet table; higher PEEP for severe ARDS |
| SpO2 | 88-95% |
| Permissive hypercapnia | pH ≥ 7.20 acceptable |
| Prone positioning | ≥ 16 h/day for P/F < 150 mmHg |
| NMB | Consider for severe ARDS / refractory dyssynchrony |
| Fluid strategy | Conservative after resuscitation |
| HFOV | NOT recommended routinely |
Key Sources:
- Murray & Nadel's Textbook of Respiratory Medicine (2-Volume), Chapter 134, p. 3158-3160 (ARDSNet trial, PEEP strategies, HFOV, prone positioning)
- Fishman's Pulmonary Diseases and Disorders (2-Volume), Chapter 141, p. 2493 (Berlin definition, management overview)
- Washington Manual of Medical Therapeutics, p. 289 (LPV principles, driving pressure, adjuncts)
- 2025 ARDS guideline bedside application review - ATS and ESICM guidance
- Driving pressure meta-analysis 2024 (PMID 38937217)
- Extended prone positioning meta-analysis 2026 (PMID 41631378)
- EIT for PEEP titration 2025 (PMID 40011398)
This is a shared conversation. Sign in to Orris to start your own chat.